(E)-N-[2-(3,4-dimethoxyphenyl)-2-(methylthio)ethyl]-3-(pyridin-3-yl)-2-propenoic acid amide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N-[2-(3,4-dimethoxyphenyl)-2-(methylthio)ethyl]-3-(pyridin-3-yl)-2-propenoic acid amide
• 英文别名: (E)-N-[2-(3,4-dimethoxyphenyl)-2-(methylthio)ethyl]-3-(3-pyridyl)-2-propenoic acid amide；(E)-N-[2-(3,4-dimethoxyphenyl)-2-(methylthio)ethyl]-3-(pyridin-3-yl)-2-propenamide；(E)-N-[2-(3,4-dimethoxyphenyl)-2-(methylthio)ethyl]-3-(3-pyridyl)-2-propenamide；(E)-N-[2-(3,4-dimethoxyphenyl)-2-methylsulfanylethyl]-3-pyridin-3-ylprop-2-enamide
• 化学式: C₁₉H₂₂N₂O₃S
• 分子量: 358.461
• InChiKey: ANDOWHLKLCXCMP-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  85.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(3,4-dimethoxyphenyl)-2-(methylthio)ethylamine 、 反-3(3-吡啶基)烯丙酸 、 碳酸氢钠 在 ice 、 乙酸乙酯 、 水 、 氯化钠 、 magnesium sulfate 、 silica gel 、 正己烷 、 氯仿 、 乙醇 作用下， 以 N,N-二甲基甲酰胺 、 diethylphosphoric cyanide 、 三乙胺 为溶剂， 反应 0.17h， 以to yield the titled compound (788 mg, 47%)的产率得到(E)-N-[2-(3,4-dimethoxyphenyl)-2-(methylthio)ethyl]-3-(pyridin-3-yl)-2-propenoic acid amide
  参考文献：
  名称：

  Compositions and methods for treating nephritis and inhibiting TGF -&bgr; related conditions using pyridylacrylamide derivatives

  摘要：

  本发明涉及一种用于治疗肾炎的药剂和一种TGF-β抑制剂，其有效成分为以下式(I)所表示的吡啶基丙烯酰胺衍生物，其中Ar1是取代或未取代的吡啶基，Ar2是取代或未取代的苯基，R1是氢原子、烷基或芳基，R2是氢原子、烷基、氰基或烷氧羰基，R3是氢原子或可选取代的烷基，X是氧原子或硫原子，A和B相同或不同，分别表示氢原子、羟基、烷氧基或烷硫基，或A和B一起形成氧化物或硫化物基团，或者由公式═N-Y表示的基团，其中Y是二烷基氨基、羟基、芳基烷氧基或烷氧基，或由公式—Z1—M—Z2—表示的基团，其中Z1和Z2相同或不同，分别表示氧原子或硫原子，或可选用烷基取代的亚胺基团，M是烷基或1,2-苯基，或者A是羟基，B是1-烷基咪唑-2-基基团，n为1到3的整数，或其药学上可接受的盐；以及吡啶基丙烯酰胺衍生物。

  公开号：

  US06313153B1

文献信息

• PHOSPHODIESTERASE IV INHIBITOR CONTAINING PYRIDYLACRYLAMIDE DERIVATIVE
  申请人：TSUMURA & CO.

  公开号：EP1495757A1

  公开（公告）日：2005-01-12

  This invention relates to a phosphodiesterase IV inhibitor containing as an active ingredient a pyridylacrylamide derivative represented by the following formula (I): (wherein Ar1 represents substituted or unsubstituted pyridyl; Ar2 represents phenyl substituted by alkoxy, etc.; R1 represents hydrogen, alkyl, or aryl; R2 represents hydrogen, alkyl, cyano, or alkoxycarbonyl; R3 represents hydrogen or optionally substituted alkyl; X represents oxygen or sulfur; A and B are the same or different and each independently represents hydrogen, hydroxyl, alkoxy, or alkylthio, or A and B together represent oxo, thioxo, etc., or A may be hydroxyl and B may be 1-alkylimidazol-2-yl; and n is an integer from 1 to 3) or a pharmaceutically acceptable salt thereof.

  这项发明涉及一种磷酸二酯酶IV抑制剂，其活性成分为以下式(I)所代表的吡啶丙烯酰胺衍生物：（其中Ar1代表取代或未取代的吡啶；Ar2代表被烷氧基等取代的苯基；R1代表氢、烷基或芳基；R2代表氢、烷基、氰基或烷氧羰基；R3代表氢或可选择取代的烷基；X代表氧或硫；A和B相同或不同，每个独立代表氢、羟基、烷氧基或烷基硫基，或A和B一起代表氧代、硫代等，或A可能是羟基，B可能是1-烷基咪唑-2-基；n为1至3的整数）或其药学上可接受的盐。
• Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
  申请人：Hattori Tomohisa

  公开号：US20050187264A1

  公开（公告）日：2005-08-25

  This invention relates to a phosphodiesterase IV inhibitor containing as an active ingredient a pyridylacrylamide derivative represented by the following formula (I): (wherein Ar 1 represents substituted or unsubstituted pyridyl; Ar 2 represents phenyl substituted by alkoxy, etc.; R 1 represents hydrogen, alkyl, or aryl; R 2 represents hydrogen, alkyl, cyano, or alkoxycarbonyl; R 3 represents hydrogen or optionally substituted alkyl; X represents oxygen or sulfur; A and B are the same or different and each independently represents hydrogen, hydroxyl, alkoxy, or alkylthio, or A and B together represent oxo, thioxo, etc., or A may be hydroxyl and B may be 1-alkylimidazol-2-yl; and n is an integer from 1 to 3) or a pharmaceutically acceptable salt thereof.

  本发明涉及一种磷酸二酯酶IV抑制剂，其作为活性成分包含以下式(I)所表示的吡啶基丙烯酰胺衍生物：（其中Ar1表示取代或未取代的吡啶基；Ar2表示被烷氧基等取代的苯基；R1表示氢、烷基或芳基；R2表示氢、烷基、氰基或烷氧羰基；R3表示氢或可选择取代的烷基；X表示氧或硫；A和B相同或不同，每个独立地表示氢、羟基、烷氧基或烷基硫，或A和B在一起表示氧代、硫代等，或A可以是羟基，B可以是1-烷基咪唑-2-基；n为1至3的整数）或其药学上可接受的盐。
• PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME
  申请人：TSUMURA & CO.

  公开号：EP1000935A1

  公开（公告）日：2000-05-17

  The present invention relates to an agent for treating nephritis and a TGF-β inhibiting agent comprising as an effective ingredient a pyridylacrylamide derivative represented by the following formula (I): wherein Ar1 is a substituted or unsubstituted pyridyl group, Ar2 is a substituted or unsubstituted phenyl group, R1 is a hydrogen atom, an alkyl group or an aryl group, R2 is a hydrogen atom, an alkyl group, a cyano group or an alkoxycarbonyl group, R3 is a hydrogen atom or an optionally substituted alkyl group, X is an oxygen or sulfur atom. A and B are same or different and each represent a hydrogen atom, a hydroxyl group, an alkoxy group or an alkylthio group, or A and B together form an oxo or thioxo group, or a group represented by the formula: =N-Y in which Y is a dialkylamino, hydroxyl, aralkyloxy or alkoxy group, or a group represented by the formula: -Z1-M-Z2- in which Z1 and Z2 are same or different and each represent an oxygen or sulfur atom or an imino group optionally substituted by an alkyl group, and M is an alkylene group or a 1,2-phenylene group, or A is a hydroxyl group and B is a 1-alkylimidazol-2-yl group, and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof; as well as the pyridylacrylamide derivatives.

  本发明涉及一种治疗肾炎的制剂和一种 TGF-β 抑制剂，其有效成分包括下式 (I) 所代表的吡啶丙烯酰胺衍生物： 其中 Ar1 是取代或未取代的吡啶基，Ar2 是取代或未取代的苯基，R1 是氢原子、烷基或芳基，R2 是氢原子、烷基、氰基或烷氧羰基，R3 是氢原子或任选取代的烷基，X 是氧原子或硫原子。A 和 B 相同或不同，各自代表一个氢原子、一个羟基、一个烷氧基或一个烷硫基，或 A 和 B 共同形成一个氧代或硫代基团，或一个由式：=N-Y 所代表的基团，其中 Y 是一个二烷基氨基、羟基、芳氧基或烷氧基，或一个由式： -Z1-M-Z2- 所代表的基团，其中 Y 是一个二烷基氨基、羟基、芳氧基或烷氧基：-Z1-M-Z2-，其中 Z1 和 Z2 相同或不同，且各自代表氧原子或硫原子或任选被烷基取代的亚氨基，M 为亚烷基或 1,2-亚苯基，或 A 为羟基，B 为 1-烷基咪唑-2-基，n 为 1 至 3 的整数、 或其药学上可接受的盐；以及吡啶丙烯酰胺衍生物。
• US6313153B1
  申请人：——

  公开号：US6313153B1

  公开（公告）日：2001-11-06
• Compositions and methods for treating nephritis and inhibiting TGF -&bgr; related conditions using pyridylacrylamide derivatives
  申请人：Tsumura & Co.

  公开号：US06313153B1

  公开（公告）日：2001-11-06

  The present invention relates to an agent for treating nephritis and a TGF-&bgr; inhibiting agent comprising as an effective ingredient a pyridylacrylamide derivative represented by the following formula (I): wherein Ar1 is a substituted or unsubstituted pyridyl group, Ar2 is a substituted or unsubstituted phenyl group, R1 is a hydrogen atom, an alkyl group or an aryl group, R2 is a hydrogen atom, an alkyl group, a cyano group or an alkoxycarbonyl group, R3 is a hydrogen atom or an optionally substituted alkyl group, X is an oxygen or sulfur atom, A and B are same or different and each represent a hydrogen atom, a hydroxyl group, an alkoxy group or an alkylthio group, or A and B together form an oxo or thioxo group, or a group represented by the formula: ═N—Y in which Y is a dialkylamino, hydroxyl, aralkyloxy or alkoxy group, or a group represented by the formula: —Z1—M—Z2— which Z1 and Z2 are same or different and each represent an oxygen or sulfur atom or an imino group optionally substituted by an alkyl group, and M is an alkylene group or a 1,2-phenylene group, or A is a hydroxyl group and B is a 1-alkylimidazol-2-yl group, and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof; as well as the pyridylacrylamide derivatives.

  本发明涉及一种用于治疗肾炎的药剂和一种TGF-β抑制剂，其有效成分为以下式(I)所表示的吡啶丙烯酰胺衍生物，其中Ar1是取代或未取代的吡啶基团，Ar2是取代或未取代的苯基团，R1是氢原子、烷基或芳基，R2是氢原子、烷基、氰基或烷氧羰基，R3是氢原子或可选择取代的烷基，X是氧原子或硫原子，A和B相同或不同，每个代表氢原子、羟基、烷氧基或烷基硫基，或A和B一起形成氧代或硫代基，或由式表示的基团：═N—Y，其中Y是二烷基氨基、羟基、芳基氧基或烷氧基，或由式表示的基团：—Z1—M—Z2—，其中Z1和Z2相同或不同，每个代表氧原子或硫原子或可选择由烷基取代的亚胺基，M是烷基或1,2-苯基，或A是羟基且B是1-烷基咪唑-2-基，n为1至3的整数，或其药学上可接受的盐；以及吡啶丙烯酰胺衍生物。